The finding of DSC1 as a novel negative regulator of ABCA1-dependent HDL biogenesis and the identification of DTX as a potent inhibitor of the DSC1 action have opened a new horizon for developing ABCA1-directed therapies for ASCVD. The gene discussed is DSC1; the disease is atherosclerosis.